ASCO 2022 GI Cancers

CME

Key Studies in Gastrointestinal Cancers: Independent Conference Coverage of the 2022 ASCO Annual Meeting

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: August 31, 2022

Expiration: August 30, 2023

Christopher H. Lieu
Christopher H. Lieu, MD
Rachna Shroff
Rachna Shroff, MD, MS

Activity

Progress
1
Course Completed

In this activity, Christopher H. Lieu, MD, and Rachna Shroff, MD, review key gastrointestinal (GI) cancer studies presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, focusing on new data surrounding the treatment of colorectal, hepatobiliary, and pancreatic cancers.

Please note that the slide thumbnails in this activity link to brief PowerPoint slidesets, each focused on the specific study or topic of interest. These slidesets may be downloaded by clicking on any of the thumbnails within the activity.

Clinical Care Options plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity, and once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with GI cancers do you provide care for in a typical month?

A patient arrives in your care with previously untreated metastatic colorectal cancer (mCRC) with wild-type RAS and BRAF; his primary tumor was left sided. He has good performance status and no significant comorbidities; no other actionable biomarkers were identified.

Based on ASCO 2022 results from the PARADIGM study, which of the following would you be most likely to recommend for this patient in your current practice?

In a recent phase II study presented by Cercek and colleagues, all of the patients with locally advanced rectal cancer who were treated with neoadjuvant dostarlimab achieved a clinical complete response (cCR) without chemoradiotherapy or surgery. Which of the following biomarkers was used to select patients enrolled in this study?

The single-arm, phase II HERB study examined trastuzumab deruxtecan (T-DXd) in patients with unresectable or recurrent HER2-expressing biliary tract cancers (BTCs). Which of the following best describes the results presented at ASCO 2022 from this study?